|

BMS-986253 Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Anti-IL-8, Anti-IL8

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Yana Najjar1
  • The Netherlands Cancer Institute1

Indications

  • Cancer2
  • Molecular Mechanisms of Pharmacological Action1
  • Antineoplastic Agents, Immunological1
  • Unresectable Solid Tumors1
  • Antineoplastic Agents1

Other1 trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
Phase 2

Chicago, Illinois1 trial

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

University of Chicago Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.